Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666. [Epub ahead of print]

PMID:
30637900
2.

Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.

Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE.

N Engl J Med. 2018 Dec 13;379(24):2319-2329. doi: 10.1056/NEJMoa1807801.

PMID:
30575473
3.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30879-0. doi: 10.1016/j.eururo.2018.11.022. [Epub ahead of print]

PMID:
30497883
4.

Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?

Ghoshal A, Garmo H, Hammar N, Jungner I, Malmström H, Walldius G, Van Hemelrijck M.

BMC Cancer. 2018 Nov 26;18(1):1169. doi: 10.1186/s12885-018-5098-7.

5.

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M.

Cancer Causes Control. 2018 Nov 12. doi: 10.1007/s10552-018-1093-1. [Epub ahead of print]

PMID:
30421156
6.

Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.

Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, Van Hemelrijck M.

Acta Oncol. 2018 Oct 30:1-9. doi: 10.1080/0284186X.2018.1529427. [Epub ahead of print]

PMID:
30375907
7.

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.

Birgegård G, Folkvaljon F, Garmo H, Holmberg L, Besses C, Griesshammer M, Gugliotta L, Wu J, Achenbach H, Kiladjian JJ, Harrison CN.

Leuk Res. 2018 Nov;74:105-109. doi: 10.1016/j.leukres.2018.10.006. Epub 2018 Oct 11.

PMID:
30368038
8.

Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.

Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P.

BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563. [Epub ahead of print]

PMID:
30253031
9.

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, Van Hemelrijck M, Lambe M.

Breast Cancer Res Treat. 2018 Nov;172(1):167-177. doi: 10.1007/s10549-018-4890-z. Epub 2018 Jul 21.

10.

Reply to the letter to the editor 'Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies' by X. Dong, G. Ma and F. Chen.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P.

Ann Oncol. 2018 Sep 1;29(9):2020-2021. doi: 10.1093/annonc/mdy236. No abstract available.

PMID:
29992285
11.

Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus.

Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L.

Int J Cancer. 2018 Oct 15;143(8):1868-1875. doi: 10.1002/ijc.31587. Epub 2018 Aug 10.

12.

Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ.

Wadsten C, Wennstig AK, Garmo H, Nilsson G, Blomqvist C, Holmberg L, Fredriksson I, Wärnberg F, Sund M.

Breast Cancer Res Treat. 2018 Aug;171(1):95-101. doi: 10.1007/s10549-018-4803-1. Epub 2018 May 5.

PMID:
29730730
13.

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M.

PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018.

14.

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.

BMJ Open. 2018 Mar 16;8(3):e020787. doi: 10.1136/bmjopen-2017-020787.

15.

Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M.

BMC Cancer. 2018 Feb 20;18(1):205. doi: 10.1186/s12885-018-4111-5.

16.

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, Adolfsson J, Stattin P, Carroll P, Van Hemelrijck M.

Ecancermedicalscience. 2018 Jan 25;12:802. doi: 10.3332/ecancer.2018.802. eCollection 2018. Review.

17.

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M.

Oncotarget. 2017 Dec 4;9(1):774-782. doi: 10.18632/oncotarget.22891. eCollection 2018 Jan 2.

18.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

PMID:
29322512
19.

Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.

Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P, Stattin P.

Eur Urol. 2018 Apr;73(4):502-511. doi: 10.1016/j.eururo.2017.11.039. Epub 2017 Dec 15.

20.

The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data.

Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, Holmberg L, Bill-Axelson A.

Eur J Cancer. 2018 Jan;88:101-108. doi: 10.1016/j.ejca.2017.10.023. Epub 2017 Dec 6.

PMID:
29216521
21.

Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P.

Ann Oncol. 2018 Feb 1;29(2):377-385. doi: 10.1093/annonc/mdx742.

PMID:
29161337
22.

Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).

Häggström C, Liedberg F, Hagberg O, Aljabery F, Ströck V, Hosseini A, Gårdmark T, Sherif A, Malmström PU, Garmo H, Jahnson S, Holmberg L.

BMJ Open. 2017 Sep 27;7(9):e016606. doi: 10.1136/bmjopen-2017-016606.

23.

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):260-267. doi: 10.1111/bju.14023. Epub 2017 Oct 17.

PMID:
28940667
24.

Serum biomarkers to predict risk of testicular and penile cancer in AMORIS.

Ghoshal A, Garmo H, Arthur R, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Hemelrijck MV.

Ecancermedicalscience. 2017 Aug 23;11:762. doi: 10.3332/ecancer.2017.762. eCollection 2017.

25.

Risk of death from breast cancer after treatment for ductal carcinoma in situ.

Wadsten C, Garmo H, Fredriksson I, Sund M, Wärnberg F.

Br J Surg. 2017 Oct;104(11):1506-1513. doi: 10.1002/bjs.10589. Epub 2017 Aug 22.

PMID:
28832961
26.

Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.

Eur Urol. 2017 Dec;72(6):920-928. doi: 10.1016/j.eururo.2017.06.036. Epub 2017 Jul 12.

27.

The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort.

Nderitu P, Bosco C, Garmo H, Holmberg L, Malmström H, Hammar N, Walldius G, Jungner I, Ross P, Van Hemelrijck M.

Int J Cancer. 2017 Sep 15;141(6):1148-1160. doi: 10.1002/ijc.30818. Epub 2017 Jun 21.

28.

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study.

Yiu A, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Oncotarget. 2017 Jun 27;8(26):42332-42342. doi: 10.18632/oncotarget.16198.

29.

Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):209-216. doi: 10.1111/bju.13880. Epub 2017 May 17.

PMID:
28418195
30.

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M.

BMC Cancer. 2017 Apr 4;17(1):246. doi: 10.1186/s12885-017-3232-6.

31.

Serum inflammatory markers and colorectal cancer risk and survival.

Ghuman S, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Br J Cancer. 2017 May 9;116(10):1358-1365. doi: 10.1038/bjc.2017.96. Epub 2017 Apr 4.

32.

Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.

Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, Gunnlaugsson A, Widmark A, Van Hemelrijck M.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1026-1031. doi: 10.1016/j.ijrobp.2017.01.218. Epub 2017 Feb 1.

33.

Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.

Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Breast Cancer Res. 2017 Mar 6;19(1):22. doi: 10.1186/s13058-017-0816-7.

34.

A latent class model for competing risks.

Rowley M, Garmo H, Van Hemelrijck M, Wulaningsih W, Grundmark B, Zethelius B, Hammar N, Walldius G, Inoue M, Holmberg L, Coolen ACC.

Stat Med. 2017 Jun 15;36(13):2100-2119. doi: 10.1002/sim.7246. Epub 2017 Feb 24.

PMID:
28233395
35.

Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.

Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K.

Breast Cancer Res. 2016 Dec 1;18(1):119.

36.

The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors.

Eriksson J, Garmo H, Hellman P, Ihre-Lundgren C.

Ann Surg Oncol. 2017 May;24(5):1214-1220. doi: 10.1245/s10434-016-5703-4. Epub 2016 Nov 30.

37.

Inter-observer variation in delineating the coronary arteries as organs at risk.

Wennstig AK, Garmo H, Hållström P, Nyström PW, Edlund P, Blomqvist C, Sund M, Nilsson G.

Radiother Oncol. 2017 Jan;122(1):72-78. doi: 10.1016/j.radonc.2016.11.007. Epub 2016 Nov 17.

PMID:
27866849
38.

Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.

Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J.

Eur Urol. 2017 Oct;72(4):534-541. doi: 10.1016/j.eururo.2016.10.031. Epub 2016 Nov 2.

39.

Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.

Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, Gudbjörnsdottir S, Garmo H, Stattin P.

Int J Cancer. 2017 Feb 1;140(3):611-617. doi: 10.1002/ijc.30480. Epub 2016 Nov 3.

40.

Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.

Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P.

Acta Oncol. 2016 Dec;55(12):1461-1466. Epub 2016 Oct 17.

PMID:
27749139
41.

Long-term outcome in young women with breast cancer: a population-based study.

Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, Bergh J, Holmberg L, Pontén F, Frisell J, Fredriksson I.

Breast Cancer Res Treat. 2016 Nov;160(1):131-143. Epub 2016 Sep 13.

42.

Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies.

Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M.

Int J Mol Sci. 2016 Sep 6;17(9). pii: E1487. doi: 10.3390/ijms17091487.

43.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

44.

Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56-61.

Van Hemelrijck M, Garmo H, Adolfsson J, Stattin P.

Eur Urol. 2017 Feb;71(2):e61-e62. doi: 10.1016/j.eururo.2016.08.021. Epub 2016 Aug 17. No abstract available.

PMID:
27544579
45.

Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.

Valachis A, Garmo H, Weinman J, Fredriksson I, Ahlgren J, Sund M, Holmberg L.

Breast Cancer Res Treat. 2016 Sep;159(2):293-303. doi: 10.1007/s10549-016-3928-3. Epub 2016 Aug 5.

46.

Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.

Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, Jonsson H, Bratt O.

Eur Urol. 2017 Jul;72(1):125-134. doi: 10.1016/j.eururo.2016.07.023. Epub 2016 Aug 5.

47.

Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.

Wulaningsih W, Holmberg L, Garmo H, Karagiannis SN, Ahlstedt S, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M.

Oncoimmunology. 2016 Mar 28;5(6):e1154250. doi: 10.1080/2162402X.2016.1154250. eCollection 2016 Jun.

48.

Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study.

Bratt O, Drevin L, Akre O, Garmo H, Stattin P.

J Natl Cancer Inst. 2016 Jul 10;108(10). pii: djw110. doi: 10.1093/jnci/djw110. Print 2016 Oct.

PMID:
27400876
49.

Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study.

Thorstenson A, Garmo H, Adolfsson J, Bratt O.

J Urol. 2017 Jan;197(1):61-66. doi: 10.1016/j.juro.2016.06.080. Epub 2016 Jun 17.

PMID:
27328367
50.

Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study.

Rohrmann S, Garmo H, Malmström H, Hammar N, Jungner I, Walldius G, Van Hemelrijck M.

Atherosclerosis. 2016 Aug;251:85-93. doi: 10.1016/j.atherosclerosis.2016.06.004. Epub 2016 Jun 2.

PMID:
27289190

Supplemental Content

Support Center